Hepatic Growth Hormone Resistance in young Women with Type 1 Diabetes: Comparison with controls and effects of oral and transdermal estrogen administration.

Trial Profile

Hepatic Growth Hormone Resistance in young Women with Type 1 Diabetes: Comparison with controls and effects of oral and transdermal estrogen administration.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Estrogen (Primary) ; Estrogen (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms EsTiD
  • Most Recent Events

    • 10 May 2016 Status changed from recruiting to completed.
    • 30 Oct 2014 Accrual to date is 58% according to United Kingdom Clinical Research Network record.
    • 02 Oct 2014 Planned End Date changed from 31 Jul 2014 to 30 Jun 2015 as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top